Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. present study identifies a potential prognostic biomarker CD26-targeted therapy based on data. Methods Box and Whisker plot analysis, Scatter Peason product moment correlation/Spearman’s rank-difference correlation , Bar graph Receiver Operating Characteristics (ROC) were used to examine between sCD26 titer variation with administration tumor volume change, RECIST criteria evaluation progression free survival (PFS). Mechanism serum confirmed by in vitro experimentation. Results Serum sCD26/DPP4 reduced following gradually recovered until next infusion. before infusion sustained at lower levels Stable Disease (SD) cases compared Progressive cases. ROC analysis defined cut-off level day 29 pre/post clinical outcome SD as response or PFS. In experimentation that addition production from non-tumor cells. Conclusions Our indicates early treatment is predictive evaluating therapeutic efficacy.